Investors

Initially created with the sole ressources both co-founders brought (100 K€), Neorphys has since obtained loans and subsidies (331 K€) from the Region Languedoc Roussillon, the State and the European Commission, as well as from private entities such as Oséo and Crealia.

A seed financing round has been achieved in march 2007 with venture capital companies Inserm Transfert Initiative and Soridec, then complemented by VC CEA Valorisation in july 2007. In total, 1.050 M€ have been raised.

Neorphys is currently launching a series A road show to support  the regulatory development of its most advanced visceral pain drug candidate and to expand its pain pipeline.

For more details, contact us directly: